To analyze the effect of the TRAF3 mutation in MAVER-1 cells on the activity of the alternative NFκB pathway, we treated MCL cells with the proteasome inhibitor MG132 and detected higher levels of NIK in comparison to REC-1 cells (Fig. 1a). The gene discussed is NFKB1; the disease is mantle cell lymphoma.